AZ’s Susan Galbraith On What’s Next In The Cancer Pipeline

One of the architects of AstraZeneca’s burgeoning cancer portfolio, oncology R&D head Susan Galbraith is making sure the firm does not rest on its laurels. She talked to In Vivo about what’s coming next from the UK major’s cancer pipeline.    

Missile
AZ is aiming to pick the right target for the right kind of cancer and pair it with the right warhead • Source: Shutterstock

Success is said to breed success, but for AstraZeneca PLC, recent triumphs for its oncology portfolio are not to be taken for granted. As well as diversifying its pipeline through select deals, such as the recent acquisition of TeneoTwo, Inc. to boost its hemato-oncology presence, the company is banking on success with its pipeline of novel anticancers to take its offering to the next level. Oncology chief Susan Galbraith talked to In Vivo about some of the more promising earlier candidates coming through the pipeline.

Galbraith joined AstraZeneca back in 2010 when the company was a byword for poor pipeline prospects, and she played a...

More from Leadership

More from In Vivo